Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
The Company anticipates recording restructuring charges that it currently estimates will range between $12.0 million to $15.0 million in the aggregate in the second half of fiscal 2024.
The company expects 2024 Restructuring Plan to result in $100 million of annual run-rate cost savings related to strategic streamlining of the Company's operational structure to optimize its clinical and behavioral product portfolio and to its cost-savings initiative.
Posted In: WW